CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Millions		Total		2024 General Purchase Program	Adjustment	Preferred Stock	Common Stock		Capital Surplus		Retained Earnings	Retained Earnings Adjustment	Accumulated Other Comprehensive Income (Loss)		Noncontrolling Interest
Preferred stock, balance, beginning of period (in shares) at Dec. 31, 2022						31,686,000
Common stock, balance, beginning of period (in shares) at Dec. 31, 2022							537,101,000
Balance, beginning of period at Dec. 31, 2022		$ 8,547			$ 4	$ 1,014	$ 336		$ 4,840		$ 3,430	$ 4	$ (1,368)	[1]	$ 295
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		255									251				4
Other comprehensive income		160											160	[1]
Cash dividends declared:
Preferred stock		(8)									(8)
Common stock		(82)									(82)
Common stock repurchased (in shares)							(159,000)
Common stock repurchased		(4)							(4)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)							677,000
Stock options exercised and restricted stock awards		5							5
Stock-based compensation expense		22							22
Dividends declared - noncontrolling interest of subsidiary preferred stock		(4)													(4)
Preferred stock, balance, ending of period (in shares) at Mar. 31, 2023						31,686,000
Common stock, balance, ending of period (in shares) at Mar. 31, 2023							537,619,000
Balance, end of period at Mar. 31, 2023		8,895				$ 1,014	$ 336		4,863		3,595		(1,208)	[1]	295
Preferred stock, balance, beginning of period (in shares) at Dec. 31, 2023						26,750,000
Common stock, balance, beginning of period (in shares) at Dec. 31, 2023							558,839,000
Balance, beginning of period at Dec. 31, 2023		9,291				$ 520	$ 349		5,351		3,964		(1,188)	[2]	295
Balance, beginning of period (Accounting Standards Update 2022-02) at Dec. 31, 2023		8									8
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income		197									192				5
Other comprehensive income		(83)											(83)	[2]
Cash dividends declared:
Preferred stock		(8)									(8)
Common stock		(84)									(84)
Common stock repurchased (in shares)	[3]						(11,052,000)
Common stock repurchased		(159)	[3]	$ (154)			$ (7)	[3]	(152)	[3]
Excise tax on share repurchases		(2)							(2)
Common stock issued for:
Stock options exercised and restricted stock awards (in shares)							850,000
Stock options exercised and restricted stock awards		0
Stock-based compensation expense		18					$ 1		17
Dividends declared - noncontrolling interest of subsidiary preferred stock		$ (5)													(5)
Preferred stock, balance, ending of period (in shares) at Mar. 31, 2024		26,750				26,750,000
Common stock, balance, ending of period (in shares) at Mar. 31, 2024							548,637,000
Balance, end of period at Mar. 31, 2024		$ 9,173				$ 520	$ 343		$ 5,214		$ 4,072		$ (1,271)	[2]	$ 295

[1] Due to the nature of the preferred stock issued by FHN and its subsidiaries, all components of other comprehensive income (loss) have been attributed solely to FHN as the controlling interest holder.

[2] Due to the nature of the preferred stock issued by FHN and its subsidiaries, all components of other comprehensive income (loss) have been attributed solely to FHN as the controlling interest holder.

[3] Includes $154 million repurchased under our general purchase program